Network Version
Molidustat Data Sheet
| Product Name: | Molidustat |
 |
|---|---|---|
| CAS No.: | 1154028-82-6 | |
| Cat. No.: | HY-12654 | |
| MWt: | 314.3 | |
| Formula: | C13H14N8O2 | |
| Purity : | >98% | |
| Solubility: | DMSO : 5 mg/mL (ultrasonic) | |
| Mechanisms: | Target: Cardiovascular Disease | |
| Biological Activity: | ||
|
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia[1][2].
IC50 & Target:IC50: 480 nM (PHD1), 280 nM (PHD2), 450 nM (PHD3)[1]
In Vitro:Molidustat (BAY 85-3934) (5 μM; 20 min) is sufficient to induce detectable levels of HIF-1α in HeLa cells. In a cell reporter assay, Molidustat induces expression of a firefly luciferase reporter gene under the control of a hypoxia response element promoter with a mean (± SD) EC50 of 8.4 μM (n=4)[1].
In Vivo:Molidustat (BAY 85-3934) , by stabilizing the hypoxia-inducible factor (HIF), leads to a dose-dependent increase in erythropoietin (EPO) in both Wistar rats (0.5-5 mg/kg; oral; once daily for 26 days) and cynomolgus monkeys (0.5-1.5mg/kg; once daily for 5 days)[1]. Molidustat (0.5-10 mg/kg; orally; five times weekly) can normalize the blood pressure in rat models of chronic kidney disease (CKD) and effectively alleviate renal anemia in rats with impaired renal function[1]. |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com